<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473187</url>
  </required_header>
  <id_info>
    <org_study_id>UKJ-Haffner-XLHR-08-2004</org_study_id>
    <nct_id>NCT00473187</nct_id>
  </id_info>
  <brief_title>Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets</brief_title>
  <official_title>Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <brief_summary>
    <textblock>
      X-linked hypophosphatemic rickets (XLH) is characterized by rickets, disproportionate short&#xD;
      stature, impaired renal phosphate reabsorption and vitamin D metabolism. Despite oral&#xD;
      phosphate and vitamin D treatment, most children with XLH demonstrate reduced adult height.&#xD;
      The main objective of the study is to determine the beneficial effects of recombinant human&#xD;
      growth hormone (rhGH) therapy on body proportions after 36 month in these patients. Secondary&#xD;
      objective is to monitor side effects of the therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of body proportion and final height</measure>
    <time_frame>within 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects of therapy with rhGH</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <condition>Hypophosphatemic Rickets</condition>
  <condition>Growth Disorders</condition>
  <condition>Somatropin Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tanner stages of puberty B1, G1&#xD;
&#xD;
          -  body height &lt; 2,5 SDS&#xD;
&#xD;
          -  growth velocity &lt; 75%&#xD;
&#xD;
          -  confirmed diagnosis of XLHR&#xD;
&#xD;
          -  conservative treatment for at least 1 year (phosphate, vitamin D)&#xD;
&#xD;
          -  informed consent, written agreement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  growth hormone deficiency&#xD;
&#xD;
          -  hypothyreosis&#xD;
&#xD;
          -  severe rickets&#xD;
&#xD;
          -  severe physical deformities&#xD;
&#xD;
          -  severe hyperparathyreoidism&#xD;
&#xD;
          -  chronic renal failure&#xD;
&#xD;
          -  complex syndrome involving failure to thrive&#xD;
&#xD;
          -  chronic disease with failure to thrive&#xD;
&#xD;
          -  impairment of glucose tolerance&#xD;
&#xD;
          -  Tanner stages of puberty greater than B1, G1&#xD;
&#xD;
          -  medical history of malignancy&#xD;
&#xD;
          -  therapy with growth hormone, glucocorticoides, anabolica&#xD;
&#xD;
          -  attending another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Schnabel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Childrens Hospital - Charite, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagen Staude</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Childrens Hospital, Rostock</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Haffner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Childrens Hospital, Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Childrens Hospital, Rostock</name>
      <address>
        <city>Rostock</city>
        <state>MV</state>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>May 11, 2007</last_update_submitted>
  <last_update_submitted_qc>May 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2007</last_update_posted>
  <keyword>X-linked dominant hypophosphatemic rickets</keyword>
  <keyword>growth disorders</keyword>
  <keyword>anthropometry</keyword>
  <keyword>human growth hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

